BioMed Valley Discoveries, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2001-03-30
- Employees
- 1
- Market Cap
- -
- Website
- http://biomed-valley.com
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
- Conditions
- Tumor, SolidGastrointestinal Cancer
- Interventions
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 47
- Registration Number
- NCT05221320
- Locations
- πΊπΈ
University of Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈUniversity of California San Francisco, San Francisco, California, United States
πΊπΈUniversity of Kansas Cancer Center, Fairway, Kansas, United States
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
- Conditions
- Advanced Solid TumorBRAF Gene MutationBRAF Gene AlterationMEK MutationMEK AlterationMAP2K1 Gene MutationMAP2K1 Gene AlterationMAP2K2 Gene MutationMAP2K2 Gene Alteration
- Interventions
- Drug: Physician's Choice
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 104
- Registration Number
- NCT04488003
- Locations
- πΊπΈ
Mayo Clinic, Rochester, Minnesota, United States
πΊπΈHoag Memorial Hospital Presbyterian, Newport Beach, California, United States
πΊπΈChristiana Care Health Services / Helen F. Graham Cancer Center, Newark, Delaware, United States
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
- Conditions
- Healthy
- Interventions
- Drug: [14C]-BVD-523
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT02994732
Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 53
- Registration Number
- NCT02296242
- Locations
- πΊπΈ
UCLA Medical Center, Los Angeles, California, United States
πΊπΈWinship Cancer Institute of Emory University, Atlanta, Georgia, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
- Conditions
- Solid Tumor Malignancies
- Interventions
- Biological: Clostridium novyi-NT spores
- First Posted Date
- 2013-08-16
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01924689
- Locations
- πΊπΈ
Washington University School of Medicine, Saint Louis, Missouri, United States
πΊπΈAlbert Einstein College of Medicine, Bronx, New York, United States
πΊπΈMemorial Sloan Kettering Cancer Center, New York, New York, United States
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 136
- Registration Number
- NCT01781429
- Locations
- πΊπΈ
UCLA Med-Hematology & Oncology, Los Angeles, California, United States
πΊπΈYale Cancer Center, New Haven, Connecticut, United States
πΊπΈFlorida Cancer Specialists and Research Group (Sarah Cannon Research Institute), Sarasota, Florida, United States
[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection
- Conditions
- Diabetic Foot Infection
- Interventions
- Radiation: [124I]FIAU
- First Posted Date
- 2013-01-10
- Last Posted Date
- 2016-04-08
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 4
- Registration Number
- NCT01764919
- Locations
- πΊπΈ
The University of Arizona, Tucson, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈUniversity of Pennsylvania, Philadelphia, Pennsylvania, United States
[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint
- Conditions
- Prosthetic Joint Infections
- Interventions
- Radiation: [124I]FIAU
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 23
- Registration Number
- NCT01705496
- Locations
- πΊπΈ
Coastal Clinical Research, Inc., Mobile, Alabama, United States
πΊπΈTucson Orthopaedic Institute, Tucson, Arizona, United States
πΊπΈUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Biodistribution and Dosimetry Evaluation of [124I]FIAU
- Conditions
- Prosthesis Related Infections
- Interventions
- Radiation: [124I]FIAU
- First Posted Date
- 2011-04-19
- Last Posted Date
- 2013-06-27
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01337466
- Locations
- πΊπΈ
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
πΊπΈSinai Hospital of Baltimore, Baltimore, Maryland, United States
πΊπΈNorth Shore long Island Jewish Medical Center, Lake Success, New York, United States
Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies
- Conditions
- Solid Tumor Malignancies
- Interventions
- Biological: Clostridium novyi-NT spores
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- BioMed Valley Discoveries, Inc
- Target Recruit Count
- 5
- Registration Number
- NCT01118819
- Locations
- πΊπΈ
Washington University School of Medicine, St. Louis, Missouri, United States
πΊπΈMontefiore Medical Center, Bronx, New York, United States